Swedish biotech company Sprint Bioscience carries out preclinical development in cancer, with the aim of early outlicensing of its pharmaceutical projects. The pharmaceutical industry is constantly looking for exciting new projects, with a great example being last week´s digital edition of the partnering conference BIO-Europe Spring, where there was great interest in company’s projects. BioStock spoke to the company’s Chief Scientific Officer Martin Andersson and Business Development Manager Anne-Marie Wenthzel who commented on the conference.
Read the full article at biostock.se:
This is a press release from BioStock – Connecting Innovation & Capital.https://www.biostock.se